FC:AI ONE VIEW — RUSS READ-BARROW Correct as at 21 October 2026, latest version: https://fcancerwith.ai/my-one-view/card Shared by me, from my own records. Not medical advice. PATIENT ------- Name: Russ Read-Barrow Allergies: No known drug allergies Performance: WHO performance status 0 (24 Aug 2026) Contact: russreadbarrow@gmail.com DIAGNOSIS --------- Moderately differentiated adenocarcinoma, rectosigmoid colon. Stage IV. ypT4a ypN1b (3/24 nodes) M1a V+. Treatment began Dec 2021; primary resected Mar 2022. Current sites: Lungs, mediastinal lymph nodes, liver segment VII (new, Jul 2026). Also: Smouldering myeloma (diagnosed end of 2021, under haematology surveillance) Also: Gilbert's syndrome (can raise bilirubin) MOLECULAR PROFILE ----------------- KRAS/NRAS wild-type, BRAF wild-type, pMMR / MSS, HER2 IHC 0, TMB-low, 3 Mut/Mb, PD-L1 <1% (22C3, 28-8), . APC p.S1415Rfs*4: Frameshift, tissue MAF 8.5%, cfDNA 0.62% (pathogenic). TP53 p.R342*: Nonsense, tissue MAF 9.21% (pathogenic). Variants of unknown significance: RUNX1T1, FANCM, CIC, BCR, CYP2D6. Exploratory (Astron/ICC): MTOR and VEGFR1/2 protein positivity, HMGB1 overexpression. Source: EXACTA report, 1 Sep 2025. CURRENT TREATMENT ----------------- FOLFIRI + cetuximab (rechallenge, 3rd block), every 14 days. Cycles: C1 19 Aug 26; C2 2 Sep 26; C3 16 Sep 26; C4 30 Sep 26 (current); C5 14 Oct 26; C6 TBC. Doses (per cycle): Cetuximab 500 mg/m² 1000 mg Irinotecan 180 mg/m² 400 mg 5-FU bolus 400 mg/m² 900 mg 5-FU infusion (46h) 2400 mg/m² 5000 mg Folinic acid 350 mg Full doses, dose-banded. BSA 2.08 m² (84.5 kg, 185 cm, 16 Sep 26). Plan: 8–12 weeks, then consider maintenance 5-FU + cetuximab if response is good. CT the week of 2 November, results 9 or 10 November. CEA (UG/L) ---------- 17/04/25 66.1; 01/05/25 85.4; 19/05/25 68.2; 02/06/25 30.5; 16/06/25 17.5; 30/06/25 11.4; 11/08/25 15.6; 07/10/25 32.1; 24/11/25 44.6; 06/01/26 41.7; 02/03/26 38.6; 16/03/26 32.5; 30/03/26 21.1; 20/04/26 16.8; 12/05/26 15.8; 23/07/26 49.4; 07/08/26 87.6; 01/09/26 146; 14/09/26 50.9; 29/09/26 44.6; 12/10/26 47.3. Normal range approx. 0-5 (lab-dependent). KEY BLOODS, 12 OCTOBER 2026 --------------------------- Haemoglobin 129 g/L (range 130–170) LOW Red cells 4.13 ×10¹²/L (range 4.40–5.80) LOW White cells 9.79 ×10⁹/L (range 3.0–10.0) Neutrophils 6.84 ×10⁹/L (range 2.0–7.5) Lymphocytes 1.95 ×10⁹/L (range 1.2–3.65) Monocytes 0.80 ×10⁹/L (range 0.2–1.0) Platelets 290 ×10⁹/L (range 150–400) RDW 15.2 % (range 11.5–15.0) HIGH ALT 30 U/L (range 10–50) AST 39 U/L (range 10–50) ALP 190 U/L (range 30–130) HIGH GGT 28 U/L (range 10–71) Bilirubin 14 µmol/L (range 0–20) Albumin 44 g/L (range 35–50) Globulin 35 g/L (range 19–35) Adjusted calcium 2.47 mmol/L (range 2.2–2.6) Phosphate 1.27 mmol/L (range 0.8–1.5) Creatinine 72 µmol/L (range 59–104) eGFR >90 mL/min/1.73m² Sodium 136 mmol/L (range 133–146) Potassium 4.0 mmol/L (range 3.5–5.3) Urea 3.3 mmol/L (range 2.5–7.8) Chloride 98 mmol/L (range 95–108) Magnesium 0.86 mmol/L (range 0.7–1.0) LATEST IMAGING -------------- 23 Jul 2026, CT chest, abdomen & pelvis: Compared with May 2026: left perihilar soft tissue up from 3.9 cm to 6.0 cm with distal atelectasis; right lower lobe up from 3.3 cm to 4.2 cm; additional pulmonary nodules new or enlarging; mediastinal nodes increased, particularly subcarinal; new low- density lesion in hepatic segment VII, considered recurrent disease. Portal vein patent. No peritoneal disease, ascites, abdominopelvic adenopathy or aggressive bone lesion. 12 May 2026, CT chest, abdomen & pelvis: “Good response to treatment within the mediastinum and lungs.” Compared with January 2026. End of the Feb–May 2026 block. TREATMENT HISTORY ----------------- Dec 21–Feb 22 Neoadjuvant XELOX ×4, good partial response Mar–Oct 22 Primary resected, liver met resected (R0), adjuvant CAPOX Oct 22–Apr 23 Lung mets appear, progress, SABR 55 Gy/5 Jun & Aug 24 Lung ablations (1 left, then 1 left + 4 right) Feb 25 EBUS confirms mediastinal nodal disease Apr–Jul 25 FOLFIRI + cetuximab ×6, good partial response Feb–May 26 Rechallenge ×6, good response (CT 12 May) Jul–Aug 26 Progression during the break, FOLFIRI + cetuximab restarted 19 Aug MEDICATION ---------- Chemo day: Standard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine), pegfilgrastim 24h after. Supportive: Dexamethasone ×3 days, domperidone, loperamide, doxycycline + Plazon (skin), Laxido, antihistamine, zopiclone PRN. Other: Citalopram 30 mg (breakfast), melatonin 60 mg (evening), metformin MR 500 mg twice daily (from cycle 5 day 7), loratadine 10 mg. Paused: Mistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice. WHAT'S NEXT ---------- - CT scan the week of 2 November 2026. - Results 9 or 10 November. - Then the decisions: treat the liver lesion (surgery or ablation)? Continue, or step down (drop irinotecan)? What's the next line? Know this profile? Patients with similar disease, oncologists, scientists and geneticists — I want to hear from you. Not generic advice, please. Full record, source documents and data: https://fcancerwith.ai/full-record